Highstar Unveils Next-Gen Tabless Cell Series at The Battery Show Europe 2025
STUTTGART, Germany, June 5, 2025 /PRNewswire/ -- Highstar launched its next-generation Tabless Cell…
Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million
THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR…
Seoul Releases Global Tourism Campaign Featuring Star Chef Edward Lee
Seoul Tourism Organization to globally launch promotional videos featuring star Chef Edward…
New Policy Brief from the NDC Partnership Guides Countries Toward Tripling Renewable Energy
The NDC Partnership released a new policy brief today to support policymakers…
GRVT Introduces Retail Price Improvement Orders, Bringing Proven TradFi Execution Benefits Onchain
SINGAPORE, June 4, 2025 /PRNewswire/ -- GRVT, the world's first licensed onchain…
Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of 4.00
Press release Maxim Group initiates the coverage of the CROSSJECT share with…
OHI Group S.A. Announces Consent Solicitation Relating to its U.S.$400,000,000 13.000% Senior Secured Amortizing Notes due 2029 Regulation S Notes: CUSIP L7S61M AB5, ISIN USL7S61MAB59 Rule 144A Notes: CUSIP 67712M AB5, ISIN US67712MAB54 (the “Notes”)
Executive Summary — As previously announced, OHI Group S.A. (the "Issuer") is preparing…
UnitedHealth Group Announces Earnings Release Date
--(BUSINESS WIRE)--UnitedHealth Group (NYSE: UNH) will release its second quarter 2025 financial…
Press Release Biocartis NV: Biocartis Announces IVDR Class C CDx Certification of the Idylla EGFR Mutation Test
PRESS RELEASE 02/06/2025, 10:00 CEST Biocartis Announces IVDR Class C CDx Certification…
![Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]](https://i0.wp.com/ml-eu.globenewswire.com/media/NjEzMmQ4NzAtZTBkMS00ZDhhLTkyYjgtOGM3YzY1ZWM5M2U5LTEwMTQyODItMjAyNS0wNi0wMi1lbg==/tiny/Sandoz-International-GmbH.png?w=420&resize=420,280&ssl=1 "Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]")
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA…